Tirapelli Carlos R, De Andrade Claudia R, Lieberman Marcel, Laurindo Francisco R, De Souza Heraldo P, de Oliveira Ana M
Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Toxicol Appl Pharmacol. 2006 May 15;213(1):10-7. doi: 10.1016/j.taap.2005.09.001. Epub 2005 Oct 26.
We aimed to investigate the mechanisms underlying the vascular effects induced by phylloquinone (Vitamin K1; VK1). Vascular reactivity experiments, using standard muscle bath procedures, showed that VK1 (5 and 50 microM) enhances the contractile response of endothelium-intact, but not denuded, rat carotid rings to phenylephrine. Similarly, maximal contraction induced by phenylephrine was enhanced in the presence of the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME). The combination of L-NAME and VK1 did not produce any further additional effect. Pre-incubation of intact-rings with VK1 reduced both acetylcholine- and bradykinin-induced relaxation. VK1 induced an increment in tension on carotid rings submaximally pre-contracted with phenylephrine. VK1-induced increment in tension was completely abolished by endothelial removal or incubation of intact rings with L-NAME and L-NNA. Conversely, 7-nitroindazole, 1400 W, or indomethacin did not affect VK1-induced contraction. Moreover, VK1 reduced L-arginine-induced relaxation in endothelium-intact rings. Lucigenin-amplified chemiluminescence assays showed that VK1 induced an increase in the level of superoxide anions in endothelium-intact but not denuded rings. Measurement of nitrite and nitrate generation showed that VK1 did not alter nitrate formation but strongly inhibited the generation of nitrite. Finally, the superoxide anions scavenger tiron prevented the endothelial vasomotor dysfunction caused by VK1 on phenyleprine-induced contraction and acetylcholine or bradykinin-induced relaxation. In conclusion, our data show that VK1 disrupts the vasomotor function of rat carotid. Our results suggest that VK1-induced oxidative stress through production of superoxide anion is interfering with the NO pathway, which in turn is responsible for the altered vascular reactivity induced by VK1.
我们旨在研究叶绿醌(维生素K1;VK1)诱导血管效应的潜在机制。采用标准肌肉浴程序进行的血管反应性实验表明,VK1(5和50微摩尔)增强了完整内皮(而非去内皮)大鼠颈动脉环对去氧肾上腺素的收缩反应。同样,在一氧化氮(NO)合酶抑制剂NG-硝基-L-精氨酸甲酯(L-NAME)存在的情况下,去氧肾上腺素诱导的最大收缩增强。L-NAME与VK1联合使用未产生任何进一步的附加效应。用VK1预孵育完整环可降低乙酰胆碱和缓激肽诱导的舒张。VK1使预先用去氧肾上腺素亚最大收缩的颈动脉环张力增加。去除内皮或用L-NAME和L-NNA孵育完整环可完全消除VK1诱导的张力增加。相反,7-硝基吲唑、1400W或吲哚美辛不影响VK1诱导的收缩。此外,VK1降低了完整内皮环中L-精氨酸诱导的舒张。光泽精增强化学发光分析表明,VK1使完整内皮环(而非去内皮环)中的超氧阴离子水平升高。亚硝酸盐和硝酸盐生成的测量表明,VK1不改变硝酸盐的形成,但强烈抑制亚硝酸盐的生成。最后,超氧阴离子清除剂钛铁试剂可预防VK1对去氧肾上腺素诱导的收缩以及乙酰胆碱或缓激肽诱导的舒张所引起的内皮血管舒缩功能障碍。总之,我们的数据表明VK1破坏了大鼠颈动脉的血管舒缩功能。我们的结果表明,VK1通过产生超氧阴离子诱导氧化应激,干扰了NO途径,进而导致VK1诱导的血管反应性改变。